Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Agency for Care Effectiveness
Drug guidance

Selpercatinib for advanced or metastatic thyroid cancer with RET alterations

Condition

Cancer

1 July 2026

-

Published on 01 Jul 2026
Last Updated on 01 Jul 2026

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended:

  • Selpercatinib 40 mg and 80 mg capsules and tablets as monotherapy for:

    • patients 12 years of age and older with advanced or metastatic medullary thyroid cancer with a rearranged during transfection (RET) mutation who require systemic therapy; and

    • patients 12 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).

in view of clinical need, and acceptable clinical effectiveness, safety, and pricing proposal by the company.

Funding status

Selpercatinib 40 mg and 80 mg capsules and tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications from 1 September 2026.

Clinical indications, subsidy class and MediShield Life claims eligibility for selpercatinib are provided in the Annex.

Guidance_Selpercatinib for advanced or metastatic thyroid cancer with RET alterations (1 Jul 2026) [PDF, 205.86 KB]


Back to top